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SARCOCYSTIS NE URONA DIAGNOSTIC
PRIMER AND ITS USE IN METHODS OF

cellular spaces or in cells of the spinal cord. Pericytes of

EQUINE PROTOZOAL

but the cytoplasm of neurons, macrophages, intravascular

capillaries Were most frequently parasitiZed by meroZoites,

MYELOENCEPHALITIS DIAGNOSIS

and tissue neutrophils, and axons of myelinated nerve ?bers

TECHNICAL FIELD

the cytoplasm of tissue and circulating neutrophils suggest

The present invention relates to an ampli?cation primer
and probe Which can be used in an in vitro diagnostic test for
the presence of S. neurona in equine blood or cerebrospinal
?uid.
Sarcocystis neurona is responsible for the equine condi

also contained these organisms. The presence of parasites in

10

that this putative Sarcocystis sp. may have a hematogenous
phase of infection.
“Immunohistochemical study to demonstrate Sarcocystis
neurona in equine protoZoal myeloencephalitis”, Hamir et

al., J. Vet. Diagn. Invest. (UNITED STATES) July 1993, 5
(3) p418—22; discloses a 5-year (1985—1989) retrospective

tion of protoZoal myelitis. The ampli?cation primer is sev

immunohistochemical study Was conducted using an avidin

enteen nucleotides in length and complementary to a unique
section of the small ribosomal subunit of Sarcocystis
neurona, nucleotide positions 1470—1487. The primer has
the sequence 5‘ CCATTCCGGACGCGGGT-3‘(SEQ ID

biotin complex (ABC) immunoperoxidase method to dem
15

onstrate Sarcocystis neurona in histologically suspect cases

of equine protoZoal myeloencephalitis (EPM). Primary anti
bodies against S. neurona and S. cruzi Were utiliZed for the

N011).

ABC technique. The ?ndings Were compared With those
from cases in Which the organisms Were detected by exami
BACKGROUND

20

nation of hematoxylin and eosin (HE)-stained neuronal

25

sections. HE-stained sections detected the presence of the
organisms in 20% of the suspect cases; Whereas the ABC
technique con?rmed the presence of S. neurona in 51% and
67% of the cases by S. neurona and S. cruzi antibodies,
respectively. A revieW of clinical case histories shoWed that

Equine protoZoal myeloencephalitis (EPM) is a treatable,
but often fatal, central nervous system (CNS) disease of
equids. It has not been reported among horses originating
outside the Western hemisphere. Several hundred cases
occur in North America annually. Although EPM has been

21/47 (45%) of the EPM horses With parasites in the tissue
sections had prior treatment With antiprotoZoal drugs and/or

reported in ponies, donkeys and most breeds of horses, the
greatest incidence has been among thoroughbreds,
standardbreds, and quarter horses.1 (See references section
beloW.) The disease occurs as a result of infection With

Sarcocystis neurona. MeroZoites multiply in neurons, leu
cocytes and vascular endothelial cells of the CNS resulting
in perivascular mononuclear cell in?ltration and necrosis of

30

“Equine protoZoal myeloencephalitis: Antigen analysis of
cultured Sarcocystis neurona meroZoites”, Granstrom et al.,

the neuropile. Antemortem diagnosis of EPM is dif?cult.2
Clinical signs vary dramatically, depending upon the loca
tion and severity of CNS lesions. The disease may mimic

35

40

cephalitis (EPM), and pre-suckle serum from a neWborn

foal. Eight proteins, 70, 24, 23.5, 22.5, 13, 11, 10.5, and 10

an antigen or antigens of larval origin, speci?cally of Taenia

Kd, Were detected only by S. neurona antiserum and/or
45 immune serum from EPM-affected horses. Equine sera Were

titered by the indirect immuno?uorescent antibody (IFA)

against Potomac Horse Fever comprising deactivated E.

method using air-dried, cultured S. neurona meroZoites.

Risticii as the active agent. The patent also discloses an assay

for detecting the presence of E. Risticii antibodies.
US. Pat. No. 5,141,925 to Alroy et al. discloses a method
for the prophylactic and therapeutic treatment of animals

Anti-Sarcocystis IFA titers Were found in horses With or
Without EPM. Serum titers did not correspond to the number
50

55

blood.

“Evidence for Sarcocystis as the etiologic agent of equine
protoZoal myeloencephalitis”, Simpson et al., J ProtoZool

(UNITED STATES) August 1980, 27 (3) p288—92, discloses
the diagnosis of Equine protoZoal myeloencephalitis (EPM)

ings permitted tentative identi?cation of the protoZoan as a
Sarcocystis sp. Free meroZoites Were present in the extra

necropsied betWeen 1985 and 1989 at a diagnostic labora
tory of a veterinary school in North America is documented.
In this investigation over 20 per cent of the horses had

clinical neurological signs. Equine protoZoal myeloencepha
litis (caused by Sarcocystis neurona) and cervical stenotic
60

in 10 horses. By electron microscopy, schiZonts Were found
in intact host cells of the spinal cords or, more frequently,
free in the extracellular spaces. Developmental stages of
schiZonts differed morphologically, and the late stage of

schiZogony Was characteriZed by endopolygeny. These ?nd

of speci?c bands recogniZed on immunoblots.

“A ?ve year (1985—1989) retrospective study of equine
neurological diseases With special reference to rabies”,
Hamir et al., J. Comp. Pathol. (ENGLAND) May 1992, 106
(4) p411—21; discloses a retrospective study of horses

having a parasite able to cause Coccidiosis.
US. Pat. No. 5,210,018 to NuZZolo et al. discloses an

immunoenZymatic method for the detection of anti
Plasmoa'ium falclparum-sporozoite antibodies in human

analysis. Blotted proteins Were probed With S. cruzi, S.
muris, and S. neurona antisera produced in rabbits, S. fayeri
(pre- and post-infection) and S. neurona (pre- and post
inoculation) sera produced in horses, immune sera from 7

histologically con?rmed cases of equine protoZoal myeloen

test and a cerebrospinal ?uid test. The test involves detecting

solium larva.
US. Pat. No. 4,759,927 to Dutta discloses a vaccine

J. Vet. Diagn. Invest. (UNITED STATES) January 1993,
5(1) p 88—90; discloses antigens of cultured Sarcocystis
neurona meroZoites Were examined using immunoblot

various neurological disorders of the horse. Clinicopatho
logic data are frequently of little diagnostic value.
Some methods of diagnosing equine parasitic and other
infections are knoWn. For example, US. Pat. No. 4,740,456
to Kuhn et al. discloses immunological methods for diag
nosing active human neurocysticercosis, including a serum

steroids. Using the test results of S. neurona and S. cruzi as
a standard reference, HE test sensitivity based on examina
tion of up to 30 neuronal sections per case Was only 25%,
and test speci?city Was 91%.

65

myelopathy (Wobbler syndrome) Were the most common of
these disorders. HoWever, only four cases of equine rabies
Were diagnosed during the 5-year study. The gross micro
scopical and immunohistochemical ?ndings from these
rabies-positive horses are documented. Immunoperoxidase
tests for detection of rabies antigen in another 35 horses With
non-speci?c encephalitis/encephalopathydid not reveal any
positive cases. Based on this investigation, it appears that

6,110,665
3

4

immunoperoXidase is a valid method for diagnosis of rabies

screening of several groups of horses in central Kentucky
indicated that many horses are eXposed While feW develop
clinical signs .4 At present, there is no method to directly

When fresh tissues are not available for the ?uorescent

antibody test.
“Characterization of Sarcocystis neurona from a thor

detect and differentiate S. neurona from non-pathogenic

oughbred With equine protoZoal myeloencephalitis”, BoW

Sarcocystis in live animals.

man et al., appears in Cornell Vet. 1992, April 82(2):115,

There is a need in the art for a diagnostic method of

Cornell Vet. (UNITED STATES) January 1992, 82 (1)

detecting Equine protoZoal myeloencephalitis (EPM). The

p41—52 and discloses morphological information for syn

type material of the etiologic agent of equine protoZoal
myeloencephalitis, Sarcocystis HQZU‘OI’LLZ. A clinical descrip

primer/probe of the present invention provides the ?rst
10

tion of the horse from Which the organism Was isolated and
the methodology used to immunosuppress the horse in an
attempt to increase parasite numbers are also given. The

[is HQZU‘OI’LLZ.

DISCLOSURE OF THE INVENTION

description includes microscopic details observed both With

light and transmission electron microscopy. Mainly stages

diagnostic primer for the diagnosis of Equine protoZoal
myeloencephalitis (EPM) caused by the parasite Sarcocysi

15

from tissue are illustrated, but information is also presented
on the development of the organism after inoculation on to

The present invention provides an ampli?cation primer/
probe Which can be used in an in vitro diagnostic test for the
presence of S. neurona in equine blood or cerebrospinal

monolayers of bovine monocytes. It is believed that the large

?uid. Sarcocystis neurona is responsible for the equine

numbers of organisms observed in this horse Were due to its

condition of protoZoal myelitis.

having not received prior treatment With trimethoprimsul
phonamide and the large amounts of corticosteroids that

20

The above and other objects of the invention Will become
readily apparent to those of skill in the relevant art from the

Were administered in order to facilitate isolation of the

folloWing detailed description and ?gures, Wherein only the

pathogen.

preferred embodiments of the invention are shoWn and

“Sarcocystis neurona n. sp. (Protozoa: ApicompleXa), the

etiologic agent of equine protoZoal myeloencephalitis”,

25

Dubey et al., J Parasitol (UNITED STATES) April 1991, 77
(2) p212—8; discloses Sarcocystis neurona n. sp. is proposed
for the apicompleXan taXon associated With myeloencepha
litis in horses. Only asexual stages of this parasite presently
are knoWn, and they are found Within neuronal cells and

the invention.
30

leukocytes of the brain and spinal cord. The parasite is
located in the host cell cytoplasm, does not have a parasi

muris, S. gigantea, T gondii, S. capicanis, S. arieticanis, S.

are 5—35 microns ><5—20 microns and contain 4—40 mero

cruzi, S. tenella, E. tenella and C. parvum by comparison of
35

central nucleus, and lack rhoptries. SchiZonts and meroZoi
tes react With Sarcocystis cruzi antiserum but not With

Caryospora bigenetica. Toxoplasma gondii, Hammondia
hammondi, or Neospora caninum antisera in an immuno
histochemical test.

40

“Equine protoZoal myeloencephalitis”, Madigan et al.,
Vet. Clin. North Am. Equine Pract. (UNITED STATES)

August 1987, 3 (2) p397—403; discloses Equine protoZoal
myeloencephalitis (EPM) is a disease that produces neuro
logic signs of brain or spinal cord dysfunction. The causative
organism is believed to be a Sarcocystis species of protoZoa.
A de?nitive diagnosis can only be made on histopathology

45

sequences from the small ribosomal subunit of each.
FIG. 2 shoWs a phylogenic tree depicting the relatedness

of the complete gene sequence (1806 nt) of SRSU of S.
neurona When compared to S. muris, S. gigantea, T gondii,
S. capicanis, S. arieticanis, S. cruzi, S. tenella, E. tenella and
C. parvum by comparison of sequences from the small
ribosomal subunit of each.
FIG. 3 shoWs a gel shoWing ef?cacy of the probe accord
ing to the present invention.
DESCRIPTION OF THE INVENTION

Sarcocystis neurona is the etiologic agent of Equine
protoZoal myeloencephalitis (EPM) Which Was isolated and
described in 1991. There are limited means available for

of affected spinal cord or brain. No preventive measures or
documented treatment is available at this time for suspected

antemortem detection of this protoZoan in horses, and the
life cycle and mode of transmission and pathogenesis of this

cases of EPM.

disease remain unknoWn.
The gene sequence of the Sarcocystis neurona small

Currently the only method of antemortem diagnosis of

equine sarcocystis (EPM) is by Western Blot, Which detects
the presence of antibodies against S. HQZU‘OI’LLZ. Blood con

tamination of the spinal ?uid, or loss of integrity of the
blood-brain barrier may result in false positive tests. A DNA
based test according to the present invention circumvents
these problems. Recently, progress has been made in the

BRIEF DESCRIPTION OF DRAWINGS

FIGS. 1(A)—(E) shoWs the relatedness of a 450 nt
sequence from SRSU of S. neurona When compared to S.

tophorous vacuole, and divides by endopolygeny. SchiZonts
Zoites arranged in a rosette around a prominent residual
body. MeroZoites are approximately 4><1 micron, have a

described, simply by Way of illustration of the best mode of
carrying out the invention. As is readily recogniZed the
invention is capable of modi?cations Within the skill of the
relevant art Without departing from the spirit and scope of

55

ribosomal subunit (SRSU) Was determined using poly
merase chain reaction techniques and Sanger sequencing
methods. The SRSU gene Was found to be 1806 nucleotides

(nt) in length and have a G/C content of 46%. The small

detect S. neuronal-speci?c antibodies in serum and cere

ribosomal subunit gene is an ideal molecular marker because
it contains both sequences Which are highly conserved
among species and sequences Which are variable. Variable
regions are used to determine genetic relatedness of proto

brospinal ?uid of affected horses.3 Immunoblot analysis of

Zoal organisms. For example, FIG. 1 shoWs the relatedness

these samples distinguishes betWeen eXposure to S. neurona
and S. fayeri a common, non-pathogenic, coccidia of the
horse. Previous serologic tests relied on S. cruzi bradyZoite
antigen Which only detected antibodies to shared or cross

compared to S. muris, S. gigantea, T gondii, S. capicanis, S.
arieticanis, S. cruzi, S. tenella, E. tenella and C. parvum by

development of serological methods for EPM diagnosis. The
availability of cultured meroZoites has made it possible to

reactive Sarcocystis spp. epitopes. Preliminary immunoblot

60

of a 450 nt sequence from SRSU of S. neurona When
65

comparison of sequences from the small ribosomal subunit
of each. FIG. 2 shoWs a phylogenic tree depicting the

6,110,665
5

6

relatedness of the complete gene sequence (1806 nt) of

(Novagen, Madison, Wis.) and transformed according to the

SRSU of S. neurona When compared to S. muris, S.

recommendations of the manufacturer. Transformed cells
Were selected by culturing on LB agar plates containing 50

gigantea, T gondii, S. capicanis, S. arieticanis, S. cruzi, S.
tenella, E. tenella and C. parvum by comparison of

pig/ml ampicillin and 15 pig/ml tetracycline. Colonies con
taining PCR product insert Were selected using blue/White
screening, by the addition of 40 pl of 20 mg/ml X-gal in
dimethyl formamide, and 4 pl 200 mg/ml IPTG per 100 mm

sequences from the small ribosomal subunit of each.
The present inventors have isolated an rDNA sequence
Which can be used as a species-speci?c diagnostic probe and

primer for Sarcocystis HQZU‘OI’LLZ. The methodology for iso
lating the rDNA probe is set forth beloW.
10

EXAMPLE 1

Parasite Isolation and DNA Preparation
MeroZoites of S. neurona (?fth isolate, strain SN5) Were
cultured in vitro from the spinal cord of an infected horse
Which Was necropsied at the University of Kentucky Live
stock Disease Diagnostic Center. The parasite Was main
tained in tissue culture in bovine monocytes (provided by C.

the PCR protocol described above. TWelve positive clones
15

Dideoxynucleotide Sequencing and Analysis

10% neonatal bovine serum (BioWhittaker, Walkersville,
20

sequencing reactions Were performed using these templates.
Primers used for sequencing included primers complemen

resuspended in Hanks balanced salt solution (BioWhittaker,
Walkersville, Md.). The suspension of parasites and bovine

tary to regions of the vector ?anking the insert, and also
25

1985). Additional internal primers (840E: 5‘

400><G for 20 min. MeroZoites Were found in the pellet,
While the bovine monocytes Were found at the Hanks

balanced salt solution-percoll interface.
30

phosphate-buffered saline (PBS), then resuspended in 20 pl
PBS, and 200 pl of 50% Chelex-100 (Bio-Rad, Richmond,

GGATTTCGGT TCTATTTTGT TGG 3‘(SEQ ID N012, and
1055R: 5‘ GTTTCAGCCT TGCGACCAT 3‘(SEQ ID N013)
Were designed from the partial sequence to determine the

complete sequence.

Calif). S. neurona DNA Was released by boiling this sus

pension for 5 min. The sample Was subsequently quenched
on ice for 5 min, and centrifuged. This supernatant Was used

synthetic primers complementary to conserved regions of
the eukaryotic small ribosomal subunit gene (ElWood et al.,

Louis, M0.) at a speci?c gravity of 1.070, and centrifuged at

Approximately 5><106 meroZoites Were Washed in 1 ml

Small scale plasmid puri?cations Were performed for tWo
positive clones, by a protocol modi?ed from Sambrook et al.
(1989). Alkaline denaturation of these plasmid solutions Was

performed to yield single stranded template. Sanger

Md.). Culture media Were removed from the culture vials,
centrifuged at 800><G for 20 min to pellet the cells, then

monocytes Was layered above 1 ml of Percoll (Sigma, St.

Were identi?ed in this manner, and tWo Were arbitrarily

chosen for sequencing.

A. Speer, Montana State University) supplemented With

Md.) in RPMI 1640 media (BioWhittaker, Walkersville,

plate. Plates Were incubated for 12 to 24 hours (Sambrook,
Fritsch and Maniatis, 1989). White colonies Were screened
for insert by PCR. Individual colonies Were scraped from the
plate, and diluted in 20 pl of sterile Water in 1.5 ml
microcentrifuge tubes. These Were boiled for 2 min to
release plasmid DNA, and 10 pl of supernatant Was used in

35

The complete gene sequence of the small ribosomal
subunit of S. neurona has 1806 nt. Aspeci?c 450 nt sequence
fragment from SRSU of S. neurona Was also obtained and is
disclosed.

in the polymerase chain reaction (PCR) for the ampli?cation
EXAMPLE 2

of the small ribosomal subunit gene.

DNA Ampli?cation
The PCR (Saiki et al., 1988) Was performed using eukary

otic speci?c universal ampli?cation primers developed by

Various ampli?cation primers for the SRSU gene Which
are species-speci?c for Sarcocystis neurona Were tested. The
40

Medlin et al., (1988). The described ampli?cation protocol
Was modi?ed to optimiZe DNA yield. The “hot start” tech

nique (Mullis, 1991) Was employed to limit mispriming at
the onset of the reaction. Ampli?cation primers, MgCl2, and
dNTP in PCR buffer (10 mM Tris-HCl, pH=8.3, 50 mM
KCl) Were placed in 0.5 ml microcentrifuge tubes, and

complementary to a unique section of the small ribosomal
45

primer/probe may be modi?ed at the 3‘ end by adding
1—5 nucleotides, such that the primer/probe maintains
the function of the original probe and hybridiZes spe

tant and Taq polymerase (1.25 U, Amplitaq, Perkin-Elmer,
NorWalk, Conn.) in PCR buffer Were overlaid on the Wax,
and the microcentrifuge tubes Were placed in a thermocycler

ci?cally to Sarcocystis neurona small ribosomal sub
unit.
1470R Ampli. Primer: 5‘ CCATTCCGGACGCGGGT

(Perkin-Elmer, NorWalk, Conn.). The ?nal concentrations of
reagents Were 0.5 pM of each primer, 2 mM MgCl2 and 500

pM of each deoxynucleotide.

3‘(SEQ ID N011) MW=5267

Denaturation of the DNA in the reactions Was accom

temperature Was 55° C. for 1 min, and the elongation
temperature Was 72° C. for 2 min. These sequential incu
bations Were repeated for 5 cycles, and then 30 additional
cycles Were performed at the same conditions, With the
exception of an annealing temperature of 50° C. for 1 min.
The ?nal primer extension Was continued for 7 min to permit

55

60

primer may be used as a PCR primer as set forth beloW.

EXAMPLE 3

Cloning into a pT7Blue Vector
The PCR product Was puri?ed by ultra?ltration
?ed product Was directly ligated into a pT7Blue vector

The 1470 R primer can be coupled to a detectable label
and used as a diagnostic probe for the detection of Sarcocytis
HQZU‘OI’LLZ. The detectable label may be selected from the

group consisting of chromophores, ?uorophores, chemilu
minescent materials and radioisotopes. Alternatively the

complete elongation of all ampli?ed product.

(KroWcZynska and Henderson, 1992) using microcon-100
microconcentrators (Amicon, Beverly, Mass.). The ampli

subunit of Sarcocystis HQZU‘OI’LLZ. The unique ampli?cation
primer encompasses nucleotide positions 1470—1487. The
primer has the sequence:

5‘-CCATTCCGGACGCGGGT- 3‘(SEQ ID N011). The

overlaid With 40 pl paraf?n Wax. Ten pl of Chelex superna

plished by heating to 94° C. for 1 min. The annealing

ampli?cation primer for Sarcocystis neurona SRSU With
species speci?city is seventeen nucleotides in length and
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The advent of DNA based diagnostic assays has facili
tated rapid, accurate identi?cation of micro-organisms
through the use of species-speci?c nucleotide sequences.

Generally, DNA probes have been developed from unique
gene or intergenic sequences for DNA probes, or from

6,110,665
7
repetitive elements. In addition, development of the poly
merase chain reaction (PCR) has greatly increased the speed
at Which neW diagnostic assays can be developed.5 The time
required to construct DNA libraries or clone speci?c DNA

B. LoWer Reaction Mixture

fragments has been reduced considerably by the ability to
directly amplify the desired DNA region.

‘X 1’

The methodology for the nested polymerase chain reac

tion (PCR) procedure used to conduct the diagnostic assay
according to the present invention is set forth beloW.
Nested PCR Diagnostic Method

10

5.00
5.00

1 mM
1 mM

250.00
250.00

MgCl2

8.00

4 mM

400.00

dNTPs
10 X PCRB

4.00
2.50

1 mM
1 X

200.00
125.00

2.50

5%

125.00

3.00
30.00

—
—

150.00
1500.00

f = forWard primer;
r = reverse primer

The loWer reaction mixture is made up on 50 reaction
20

quantities in a 1.5 ml microcentrifuge tube. This mixture
(labelled “#1”, and dated) may be froZen for at least 1 month
safely. When the nested reaction is to be performed, the tube

is sloWly thaWed, mixed by pipetting up and doWn, then 30.0
pl aliquots are placed into 48 blue 0.5 ml microfuge tubes.
A Wax bead (PCR gem) is placed in the tube over the
25

ice

solution. The tubes are placed in the therinocycler at 80° C.
for 5 minutes to melt the Wax, and then cooled to 4° C. to
harden the Wax. Alternatively, the tubes may be placed in a

dedicated 1000 pl, 200 pl pipetman pipettors sterile,
plugged tips for 1000 pl and 20 pl
Dedicated microcentrifuge
B. Reagents:
Millipore Water, sterilized and in 1 ml. aliquots (store in

P1184F
P1470R

15

forceps for Wax beads
1.5 and 0.5 ml tube racks

Thermocycler (48 reactions)

(,ul)

mpH2O
Reaction Volume

Wax on tin foil)

styrofoam ice cooler

Concentrations

DMSO

Blue (?rst stage)
YelloW (second stage)
PCR Wax beads (created by dropping 30 pl hot paraf?n

(#1)

(+MgCl2)

I. Required Reagents/Supplies/Equipment
A. Supplies:
Sterile 1.5 ml. microfuge tubes
Sterile 0.5 ml. microfuge tubes

Water bath (>65° C.) for about 5—10 minutes, then removed
carefully and placed in a refrigerator for a feW minutes.
30

C. Upper Reaction Mixture

freeZer)
DMSO, in 1 ml. aliquots (store aWay from light in box)

‘X 50’

Reagents

‘X 1’

35

“X 50’

Reagents

(#1)

Concentrations

(,ul)

Perkin-Elmer 10><PCR buffer

mpH2O

7.25

—

362.50

Perkin-Elmer dNTPs, 10 mM per each, mixed together to
form a single dNTP mixture containing 2.5 mM each

10 X PCRB

2.50

1 X

125.00

Taq

0.25

_

12.50

Template

10.00

—

—

Reaction Volume

20.00

—

500.00

nucleotide

40

Perkin-Elmer Mg2Cl, 25 mM Primer 1470R (unique
primer, reverse primer, ?rst stage), 10 mM, 5‘
CCATTCCGGACGCGGGT- 3‘(SEQ ID NO:1) Primer
1184F (forWard primer, ?rst stage), 10 mM

5‘ CCAGGCGTGGAGCTGCG-3‘(SEQ ID NO:4) Primer
1055F (forWard primer, second stage), 10 mM
5‘ GGTGGTGGTGCATGGCCG-3‘(SEQ ID NO:5)
Primer 1475R (reverse primer, second stage), 10 mM

5‘ GCGCGTGGCCCAGAAC-3‘(SEQ ID NO:6) (Primers

The upper reaction mixture must be made up fresh, and

chilled in ice throughout the procedure. The reagents must
45

upper reaction mixture, not including the DNA template
(CSF) is made up and then 10 pl aliquots are placed over the
Wax into the blue microcentrifuge tubes containing the loWer
50

may be synthesiZed on Applied Biosystems DNA

synthesiZer)
55

avoid cross-contamination. The tubes are numbered 1 to 48,

loWer reaction including the primers and dNTPs in PCR
60

reaction mixture. The upper reaction containing the DNA

template (in this case, cerebrospinal ?uid (CSF)) and Taq
polymerase are placed in PCR buffer on top of the Wax. A

drop (20 to 40 82 l) of sterile mineral oil is put on top to
prevent excessive evaporation from the upper reaction mix
ture. The entire tube is then spun brie?y to collect the ?uid
at the bottom of the tube.

placed into a tube, and mixed With the upper reaction
mixture by pipetting up and doWn. Care must be taken to

With numbers 1, 8, 15, 22, 29, 38, and 47 as Water, or reagent
controls. These should be done in order for internal control.
Number 48 is the positive S. neurona control. The reagent

A. The nested PCR reaction With hot start technique is set
up in several stages. First, the hot start technique requires a
buffer. The Wax is overlaid and melted over the loWer

reaction.
Forty clinical samples can be tested per run, With seven
Water controls and a positive S. neurona control. Preferably,

about ten pl of each clinical cerebrospinal ?uid (CSF) is

Ethidium Bromide

DNA 100 bp ladder
II. First Stage Reaction:

be added to the upper reaction mixture in order, so that the
PCR buffer is in the solution before the Taq is added. The

65

controls Will have the same Water tube Which Was used for

the reaction setup as the “DNA template” to control for the
accidental carryover of PCR product into this Water. Each
reaction tube should then be overlaid With a drop of sterile
mineral oil to avoid evaporation.

D. Thermal-cycle Pro?le
The tubes are placed in the thermal-cycler, and the ampli
?cation protocol folloWs:

6,110,665
10
reaction mixture, not including the DNA template (CSF) is
made up and then 10 pl aliquots are placed over the Wax into
Cycle
1

2—6

7—31

32

33

Temperature

the yelloW microcentrifuge tubes containing the loWer reac

Duration

Denaturing temp: 92 C.
Annealing temp: 58 C.
Extension temp: 74 C.
Denaturing temp: 92 C.
Annealing temp: 58 C.
Extension temp: 74 C.
Denaturing temp: 92 C.
Annealing temp: 54 C.
Extension temp: 74 C.
Denaturing temp: 92 C.
Annealing temp: 54 C.
Extension temp: 74 C.
Soak temp: 4 C.

tion.

2 min
30 min
1 min
30 sec
30 sec
1 min
30 sec
30 sec
1 min
30 sec
30 sec
7 min
Until removed

Ten pl of each blue tube (?rst stage) reaction is placed into
a tube, and mixed With the upper reaction mixture by

10

template. Each reaction tube is then overlaid With a drop of
sterile mineral oil to avoid evaporation.

D. Thermal-cycle Pro?le
15

The tubes are placed in the thermal-cycler, and the ampli
?cation protocol folloWs:

Samples are removed, and the Wax is pierced With a sterile

pipette tip. Then, 10 pl of the product is used as the DNA
template for the second stage reaction.
III. Second Stage Reaction

pipetting up and doWn. Care must be taken to avoid cross
contamination. The tubes are numbered 1 to 48, to corre
spond to the same tubes from Which product Will be used for

20

Cycle

A. It is critical that no PCR carryover occur, and therefore,
the entire procedure is done in a UV-clean area. Addition of

Temperature

1

the PCR product from the ?rst reaction, is performed in a
different area, so as not to risk contamination of “clean”
25

area.

2—6

B. LoWer Reaction Mixture
7—31

‘X 1’

‘X 50”

Reagents

(#1)

Concentrations

(,ul)

P1055F
P1475R
MgCl2

5.00
5.00
4.00

1 mM
1 mM
1 mM

250.00
250.00
200.00

dNTPs

4.50

1 mM

200.00

10 X PCRB

2.50

1 X

125.00

8.50
30.00

—
—

425.00
1500.00

mpH2O
Reaction Volume

The loWer reaction mixture is made up in 50 reaction
quantities in a 1.5 ml microcentrifuge tube. This mixture

32
30

33

Duration

Denaturing temp: 92 C.
Annealing temp: 57 C.

2 min
30 min

Extension temp: 74 C.
Denaturing temp: 92 C.
Annealing temp: 57 C.
Extension temp: 74 C.
Denaturing temp: 92 C.
Annealing temp: 53 C.
Extension temp: 74 C.
Denaturing temp: 92 C.
Annealing temp: 53 C.
Extension temp: 74 C.
Soak temp: 4 C.

1 min
30 sec
30 sec
1 min
30 sec
30 sec
1 min
30 sec
30 sec
7 min
Until removed

Samples are removed, and the Wax is pierced With a sterile
pipette tip. Then, the PCR product is run out on a horizontal
gel apparatus in a TAE 1% agarose gel at 100 V for about

2—3 hours. The band should be about 250 bp in length When
compared to the DNA 100 bp latter. Presence of a band is
40

(labelled “#2”, and dated) may be frozen for at least 1 month

determined by EtBr staining. Stained band indicates Sarco
cystis neurona is present in specimen.

safely.
When the nested reaction is to be performed, the tube is

In an alternative embodiment, the conditions for PCR

sloWly thawed, mixed by pipetting up and doWn, then 30.0
pl aliquots are placed into 48 yelloW 0.5 ml microfuge tubes.

using the species speci?c primer of the present invention
45

folloW: PCR Conditions LoWer reaction mix

A Wax bead (PCR gen) is placed in the tube over the
solution. The tubes are placed in the thermocycler at 80° C.
for 5 minutes to melt the Wax, and then cooled to 4° C. to
harden the Wax. Alternatively, the tubes may be placed in a

Water bath (>65° C.) for about 5—10 minutes, then removed

50

carefully and placed in a refrigerator for a feW minutes.
C. Upper Reaction Mixture
55
‘X 1’

Reagents

(#1)

mpH2O

10 X PCRB
Taq

‘X 50’

Concentrations

(,ul)

7.25

—

362.50

2.50

1 X

125.00
12.50

0.25

_

Template

10.00

—

Reaction Volume

20.00

1055F
1470R
MgCl2
dNTP
PCRB
DMSO

dH2O

X1

X5

X1

X5

X1

X5

2.5
2.5
3.0
4.0
2.5
5.0
7.5

12.5
12.5
30.0
20.0
12.5
25.0
37.5

2.5
2.5
4.0
4.0
2.5
5.0
9.5

12.5
12.5
20.0
20.0
12.5
25.0
47.5

2.5
2.5
8.0
4.0
2.5
5.0
5.5

12.5
12.5
40.0
20.0
12.5
25.0
27.5

Mix

60

1(N)

2(B)

Upper Rxn

Mix

Tag
Template

.25
1 #1

3(G)
X1

X13

3.25
13

—

PCRB

2.5

32.5

500.00

dH2O

16.25

211.25

The upper reaction mixture must be made up fresh, and
chilled in ice throughout the procedure. The reagents are
added to the upper reaction mixture in order, so that the PCR
buffer is in the solution before the Taq is added. The upper
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FIG. 3, shoWs a gel shoWing ef?cacy of the probe accord
ing to the present invention. Adetailed description of the gel
lanes in FIG. 3 folloW:

6,110,665
11

12
hybridization analyses indicated no sequence homology

between these fragments and the 550-bp fragment generated
from S. neurona. The S. neurona 550-bp DNA fragment also

did not hybridize With genomic blots of various other
1
2
3
4
5
*6
*7
*8
*9
*10
11
12
13
14
15
*16
*17
18
19
20
21
22
*23
*24
*25
*26
**27
*28
*29
*30
*31
**32
**33
**34

100 bp Ladder
1.0 #1 pr, 2 mM MgCl2, 10 ng DNA Templ.
1.0 #1 pr, 2 mM MgCl2, 40 ng DNA Templ.
1.0 #1 pr, 2 mM MgCl2, 80 ng DNA Templ.
1.0 #1 pr, 3 mM MgCl2, 10 DNA
1.0 ,ul pr, 3 mM MgCl2, 40 DNA
1.0 ,ul pr, 3 mM MgCl2, 80 DNA
2.5 #1 pr, 1 mM MgCl2, 10
2.5 #1 pr, 1 mM MgCl2, 40
2.5 #1 pr, 1 mM MgCl2, 80
2.5 #1 pr, 2 mM MgCl2, 10
2.5 #1 pr, 2 mM MgCl2, 40
2.5 #1 pr, 2 mM MgCl2, 80
2.5 #1 pr, 3 mM MgCl2, 10
2.5 #1 pr, 3 mM MgCl2, 40
2.5 #1 pr, 3 mM MgCl2, 80
3.0 #1 pr, 2 mM MgCl2, 10
3.0 #1 pr, 2 mM MgCl2, 40
3.0 #1 pr, 2 mM MgCl2, 80
1.0 pr, 2 mM MgCl2, DMSO, 10
1.0 pr, 2 mM MgCl2, DMSO, 40
1.0 pr, 2 mM MgCl2, DMSO, 80
2.0 pr, 3 mM MgCl2, DMSO, 10
2.0 pr, 3 mM MgCl2, DMSO, 40
2.0 pr, 3 mM MgCl2, DMSO, 80
2.5 pr, 1 mM MgCl2, DMSO, 10
2.5 pr, 1 mM MgCl2, DMSO, 40
2.5 pr, 1 mM MgCl2, DMSO, 80
2.5 pr, 2 mM MgCl2, DMSO, 10
2.5 pr, 2 mM MgCl2, DMSO, 40
2.5 pr, 2 mM MgCl2, DMSO, 80
2.5 pr, 3 mM MgCl2, DMSO, 10
2.5 pr, 3 mM MgCl2, DMSO, 40
2.5 pr, 3 mM MgCl2, DMSO, 80.

coccidia. These results evidence that the S. neurona DNA

fragment 550 bp fragment is also a species-speci?c probe for
this parasite.

Diagnostic Assay
Four geographic isolates of S. neurona Were used; SN 2
10

15

and SN 4 from California,1°’11 Sn 3 from Panama12 and Sn
5 from Kentucky. Organisms Were isolated from gross spinal
cord lesions and groWn in bovine monocyte (M617) cell
cultures as originally described by Dubey et al.13 Merozoites
Were isolated and puri?ed from cultures as previously
described by Granstrom et al.3 DNA from S. neurona, S.
cruzi, S. campestris, Toxoplasma gondii or bovine mono

cytes Was extracted using proteinase K digestion and phenol/
20

chloroform extraction as described by Gaj adhar et al.14 DNA
Was extracted from Eimeria tenella, E. falciformis, E.
nieschulzi, E. ahsata or E. bovis as outlined previously.8
Each RAPD assay consisted of a 25-;41 reaction volume
Which contained approximately 50 ng of DNA from each

25

species or geographic isolate, 1.5 OU Taq DNA polymerase
(Promega, Madison, Wis., USA) in 50 mM KCl, 10 mM
Tris-HCl, pH 9.0, 3.0 mM MgCl2, 0.01% gelatin, 0.1%
Triton X-100, 0.4 pM primer (TGF;
5‘-GCACGAACGCGCCACAAA-3‘(SEQ ID N017) and

30

200 pM of each dNTP.
The samples Were overlaid With 25 pl of mineral oil and
preincubated for 10 min at 94° C. in a DNA Thermal Cycler

model 480 (Perkin-Elmer Cetus Corporation, NorWalk,
Conn., USA). This Was folloWed by 40 cycles of 94° C. for
30 s, 38° C. for 30 s, 72° C. for 45 s, as suggested by Yu and

(*—rnarks (+) lane,

Pauls.15 After completion of the thermal cycling reaction, a

**—marks excellent probe)
35

?nal 10-min incubation at 72° C. Was performed.

DNA fragments generated by PCR Were separated by

EXAMPLE 4

electrophoresis on 1.2% agarose gels in borate buffer and
In an alternative embodiment a RAPD assay may be used

visualized by staining With ethidium bromide.16 DNA frag

to detect Sarcocystis neurona. Unlike standard PCR, the

random ampli?ed polymorphic DNA (RAPD) assays is a
procedure Which ampli?es DNA fragments Without the use
of speci?c primers, thus circumventing the need for nucle

ments unique to S. neurona Were isolated from agarose gels
40

Were labelled With [alpha-32F] dATP using Escherichia coli
DNA polymerase 1 as described by Rigby et al.17

otide sequence information and speci?c primer design.°’7
These random DNA fragments are often polymorphic
among species and isolates, behave as dominant alleles, and

by band excision and puri?ed using Quiex (Qiagen,
ChatsWorth, Calif., USA). Putative DNA probe fragments
The putative DNA probe fragments Were analyzed using

45

standard hybridization COHd1I1OI1S.16 DNA fragments Were

are inherited in a Mendelian fashion. Therefore, not only can
they be used in the same manner as restriction fragment

applied to Zeta probe GT membranes (BioRad, Hercules,

length polymorphic (RFLP) markers to characterize an
organism’s genome through genetic mapping, but also as a

from S. cruzi, S. campestris, T gondii, E. nieschulzi, E.

Calif.) and baked in vacuo at 80° C. for 2 h. Genomic DNA

ahsata, E. vermiformis, E. coli or bovine monocytes Were

means to differentiate species or isolates.8’9
50 digested With Pst 1 at 37° C. for 2 h. The resulting DNA
The present inventors utilize the RAPD assay as a means
fragments Were electrophoretically separated in a 0.75%
to differentiate four isolates of S. neurona from other coc
agarose gel and transferred to Zeta probe GT membrane by

capillary action.18
Hybridization analysis With putative S. neurona-speci?c

cidial species and have isolated a short DNA fragment Which
is useful as a speci?c DNA probe for S. neurona. Four

isolates of Sarcocystis neurona from horses With equine

55

DNA probes Was conducted at 65° C. for 12 h in 10 ml

protozoal myeloencephalitis and eight species of coccidia

hybridization buffer (5><Denhardts, 4><SSC, 0.1% SDS at 65°

from the genera Sarcocystis, Toxoplasma or Eimeria Were

C. for 30 min, and once in 0.5><SSC, 0.1% SDS for 30 min

differentiated using the random ampli?ed polymorphic DNA
(RAPD) assay. A single, common 550-bp DNA fragment

XAR-5 ?lm at —70° C. for 24 h using lighting plus inten

Was ampli?ed from the DNA of each S. neurona isolate

at the same temperature. The membranes Were exposed to
60

using a 16 nucleotide universal primer (TGF):

sifying screens.

Random ampli?ed polymorphic DNA assays using primer
TGF generated a single DNA fragment With an electro

phoretic mobility corresponding to 550 bp in all S. neurona

Cross-hybridization analysis among S. neurona isolates
shoWed that DNA fragments had at least partial sequence

homology. The primer generated several DNA fragments,
including a 550-bp DNA fragment, from S. cruzi, Eimeria
falciformis, E. neischulzi, E. ahsata and E. bovis. DNA

65

isolates. The ampli?cation of only a minute amount of
product Was detectable from isolate 3. ADNA fragment With
an identical electrophoretic mobility Was also ampli?ed
from the DNA of S. campestris, E. falciformis, E. ahsata and

6,110,665
14

13

(1988). Primer directed enZymatic ampli?cation of DNA

E. bovis, but not from bovine monocyte cells. However,
When the 550-bp DNA fragment from S. neurona (SN 2) Was
used as a probe, only those DNA fragments ampli?ed from

With a thermostable DNA polymerase. Science 239,
487—91.
6. Williams, J. G. K., Kubelik, A. R., Livak, K. J ., Rafalski,

the S. neurona isolates hybridized.

J. A. & Tingey, S. V. (1990). DNA polymorphisms ampli
?ed by arbitrary primers are useful as genetic markers.

Although 550-bp DNA fragments Were also generated
from other coccidia, the fragments did not share nucleotide
sequence homology With S. neurona. Cross-species hybrid
iZation did not occur When the 550-bp DNA fragment from
S. neurona (SN 2) Was used to probe Southern transfers of
genomic DNA isolated from bovine monocyte cells,
Escherichia coli. E. vermiformis, E. ahsata, E. nieschulzi, T
gondii, S. campestris or S. cruzi.
The RAPD assay has been successfully used to differen
tiate among closely related organisms.9>19’21 It Was found

10

that it is possible to identify unique RAPD fragments Which

15

Nucleic Acids Research 18, 6531—5.

7. Welsh, J. & McClelland, M. (1990). Fingerprinting using
PCR With arbitrary primers. Nucleic Acids Research 18.

polymorphic DNA. Veterinary Parasitology 45, 257—66.
domestic foWl using DNA polymorphisms ampli?ed by

arbitrary primers. Parasitology Research (in press).
10. Davis, S. W., Daft, B. M. & Dubey, J. P. (1991).

neurona from S. cruzi and S. campestris, as Well as T gondii
and ?ve Eimeria spp.

Sarcocystis neurona cultured in vitro from a horse With

equine protoZoal myelitis. Equine Veterinary Journal 23,
20

315—7.

11. Davis, S. W., Speer, C. A. & Dubey, J. P. (1991). In vitro
cultivation of Sarcocystis neurona from the spinal cord of
a horse With equine protoZoal myeloencephalitis. Journal

The 550-bp DNA fragment generated by the RAPD assay
has been developed into a species-speci?c probe for S.
neurona. The recognition of a putative DNA probe has
facilitated the development of a diagnostic assay for S.

8. MacPherson, J. M. & Gajadhar, A. A. (1993). Differen
tiation of seven Eimeria species by random ampli?ed

9. Procunier, J. D., Fernando, M. A. & Barta, J. R. (1993).
Species and strain differentiation of Eimeria spp. of the

could be used as species-speci?c DNA probes.
In the present study, the RAPD assay differentiated S.

These data, among geographically distinct isolates of S.
neurona, suggest that EPM is caused by a single organism.

7213—8.

of Parasitology 77, 789—92.
25

neurona based on DNA hybridiZation.

12. Granstrom, D. E., AlvareZ, O., Dubey, J. P., Comer, P. F.
& Williams, N. M. (1992). Equine protoZoal myelitis in

Sarcocystis spp. have a heteroXenous, predator-prey or

Panamanian horses and isolation of Sarcocystis neurona.

scavenger-carrion life cycle. The de?nitive host(s) and true

Journal of Parasitology 78, 909—12.
13. Dubey, J. P. Davis, S. W., Speer, C. A., BoWman, D. D.,

intermediate host(s) of S. neurona are not knoWn. Sarco

cystis of S. neurona, required for transmission to the de?ni
tive host, have not been observed in the horse.22
Consequently, the horse is considered an aberrant, dead-end

30

de Lahunta, A., Granstrom, D. E., Topper, M. J ., Hamir,
A. N., Cummings, J. F. & Suter, M. M. (1991). Sarco
cystis neurona n. sp. (ProtoZoa: ApicompleXa), the etio

host. Sarcocystis neurona probably cycles normally betWeen

logical agent of equine protoZoal myeloencephalitis,

tWo or more Wildlife species. Although many species have
been suggested as the true de?nitive host(s) of S. neurona,

Journal of Parasitology 77, 212—8.
14. Gajadhar, A. A., Marquardt, W. C., Hall, R., Gunderson,

35

J. AriZtia-Carmona, E. V. & Sogin, M. L. (1991). Ribo
somal sequences of Sarcocystis muris, Theileria annulata
and Crypthecodinium cohnii reveal evolutionary relation

skunks, raccoons or opossums are the most probable. Simi

lar to EPM, these species are broadly distributed but unique
to the Western hemisphere. Small rodents or birds are

speculative but reasonable candidates for the true interme
diate host(s) of S. neurona.
While the RAPD assay and resultant probes have imme
diate application for the differentiation of S. neurona from

other equine coccidia, an equally important use is the ability
to discern and solve the parasite’s life cycle by testing
Sarcocystis spp. from potential hosts. The availability of
infective stages Will permit the experiments necessary to
develop effective prevention and control measures for EPM.

ships among apicompleXans, dino?agellates, and ciliates.
40

2606.
45

activity in vitro by nick translation With DNA polymerase
1. Journal ofMolecular biology 113, 247—51.
18. Southern, E. M. (1975). Detection of speci?c sequences

1. Fayer, R., MayheW, I. G., Baird, J. D. et al. (1990).

Epidemiology of equine protoZoal myeloencephalitis in

among DNA fragments separated by gel electrophoresis.

North America based on histologically con?rmed cases.

Journal of molecular Biology 98, 503—17.

Journal of Veterinary Internal Medicine 4, 54—7.
2. MacKay, R. J. S., Davis, S. W. & Dubey, J. P. (1992).
55

for Practicing Veterinarians 14, 1359—66.
3. Granstrom, D. E., Dubey, J. R, Davis, S. W., Fayer, R.,

391—6.

FoX, J. C., Poonacha, K. B., Giles, R. C. & Comer, P. F.
60

DNA assay. Applied and Environmental Microbiology 57,

myeloencephalitis: Western blot analysis. Proc. 11th

2482—6.

ACVIM Forum, Washington DC, May, 1993, Pp.
587—590.

20. GoodWin, P. H. & Annis, S. L. (1991). Rapid identi?
cation of genetic variation and pathotype of Lep

tosphaeria maculans by random ampli?ed polymorphic

Journal of Veterinary Diagnostic Investigation 5, 88—90.
4. Granstrom, D. C. (1993). Diagnosis of equine protoZoal

5. Saiki, R. K., Gelfand, D. H., Stoffel, S., Scharf, S. J.,
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45 diagnostic test for the presence of S. neurona in equine blood

or cerebrospinal ?uid. Sarcocystis neurona is responsible for

the equine condition of protoZoal myelitis.
The purpose of the above description and eXamples is to
illustrate some embodiments of the present invention With
out implying any limitation. It Will be apparent to those of
skill in the art that various modi?cations and variations may
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be made to the composition and method of the present
invention Without departing from the spirit or scope of the
invention. All patents and publications cited herein are

R., Lom, J., Lynn, D., Merinfeld, E. G., Page, F. C.,

incorporated by reference in their entireties.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(iii) NUMBER OF SEQUENCES: 97

(2)

INFORMATION FOR SEQ ID NO:1 :

6,110,665
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18
-continued

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid

(c) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1 :
CCATTCCGGA CGCGGGT

l7

(2 ) INFORMATION FOR SEQ ID NO : 2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid

(c) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO : 2:
GGATTTCGGT TCTATTTTGT TGG

23

(2 ) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid

(c) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO : 3:
GTTTCAGCCT TGCGACCAT

l9

(2 ) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid

(c) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO : 4:
CCAGGCGTGG AGCTGCG

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs

l7
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20
-continued

(B) TYPE: nucleic acid

(c) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO : 5:
GGTGGTGGTG CATGGCCG

l8

(2 ) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid

(c) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO : 6:
GCGCGTGGCC CAGAAC

l6

(2 ) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid

(c) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: No
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO : 7:
GCACGAACGC GCCACAAA

l8

(2 ) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid

(c) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO : 8:
ATAGTAACCG AACGGATCGC ATTAT

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid

(c) STRANDEDNESS: single
(D) TOPOLOGY: linear

25
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-continued

(ii) MOLECULE TYPE: DNA (genomic)
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:
ATAGTAACCG AACGGATCGC ACTAT

(2)

25

INFORMATION FOR SEQ ID NO: 10 :

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid

(c) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:lO :
ATNTCGCNNT CTGAGATCGC GATNAT

(2)

26

INFORMATION FOR SEQ ID NO: 11 :

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid

(c) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:ll :
NTANNANTCC GNNNGGTTCN NNTNANT

(2)

27

INFORMATION FOR SEQ ID NO: 12 :

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid

(c) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:l2 :
ATAGTAACCG AACGGATCGC ATTAT

(2)

INFORMATION FOR SEQ ID NO: 13 :

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid

(c) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

25

